Jeffrey I Zwicker

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Tissue factor-bearing microparticles and cancer
    Jeffrey I Zwicker
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Semin Thromb Hemost 34:195-8. 2008
  2. pmc Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy
    Jeffrey I Zwicker
    Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Clin Cancer Res 15:6830-40. 2009
  3. ncbi request reprint Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia
    J I Zwicker
    Hematology Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Thromb Haemost 2:2133-7. 2004
  4. doi request reprint Measurement of platelet microparticles
    Jeffrey I Zwicker
    Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Methods Mol Biol 788:127-39. 2012
  5. doi request reprint Impedance-based flow cytometry for the measurement of microparticles
    Jeffrey I Zwicker
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Semin Thromb Hemost 36:819-23. 2010
  6. doi request reprint Predictive value of tissue factor bearing microparticles in cancer associated thrombosis
    Jeffrey I Zwicker
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, USA
    Thromb Res 125:S89-91. 2010
  7. ncbi request reprint Cancer-associated thrombosis
    Jeffrey I Zwicker
    Center for Hemostasis and Thrombosis Research, Beth Israel Deaconess Medical Center and the Department of Medicine, Harvard Medical School, Boston, MA 02115, United States
    Crit Rev Oncol Hematol 62:126-36. 2007
  8. pmc The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size
    Jeffrey I Zwicker
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Blood 108:1280-3. 2006
  9. pmc Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)
    Jeffrey I Zwicker
    Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA Division of Hematology Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Br J Haematol 160:530-7. 2013
  10. doi request reprint Tissue factor-bearing microparticles and thrombus formation
    Jeffrey I Zwicker
    Division of Hemostasis, Harvard Medical School, Thrombosis Beth Israel Deaconess Medical Center, 330 Brookline Ave E CLS 903, Boston, MA 02215, USA
    Arterioscler Thromb Vasc Biol 31:728-33. 2011

Research Grants

Detail Information

Publications12

  1. doi request reprint Tissue factor-bearing microparticles and cancer
    Jeffrey I Zwicker
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Semin Thromb Hemost 34:195-8. 2008
    ..We are currently using an impedance-based flow cytometer to accurately size and enumerate TF-bearing microparticles to explore the association between cancer thrombosis and elevations in circulating TF-bearing microparticles...
  2. pmc Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy
    Jeffrey I Zwicker
    Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Clin Cancer Res 15:6830-40. 2009
    ..We evaluated the hypothesis that tumor-derived tissue factor-bearing microparticles in plasma contribute to cancer-associated thrombosis...
  3. ncbi request reprint Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia
    J I Zwicker
    Hematology Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Thromb Haemost 2:2133-7. 2004
    ....
  4. doi request reprint Measurement of platelet microparticles
    Jeffrey I Zwicker
    Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Methods Mol Biol 788:127-39. 2012
    ..We describe methodology for light scatter-based flow cytometry as well as impedance-based flow cytometry for the enumeration and characterization of platelet microparticles...
  5. doi request reprint Impedance-based flow cytometry for the measurement of microparticles
    Jeffrey I Zwicker
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Semin Thromb Hemost 36:819-23. 2010
    ..This review details the rationale for employing impedance-based flow cytometry in the measurement of blood-borne microparticles...
  6. doi request reprint Predictive value of tissue factor bearing microparticles in cancer associated thrombosis
    Jeffrey I Zwicker
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, USA
    Thromb Res 125:S89-91. 2010
    ..This review details the evidence for tissue factor bearing microparticles in the malignant state and its association with thromboembolic phenomena...
  7. ncbi request reprint Cancer-associated thrombosis
    Jeffrey I Zwicker
    Center for Hemostasis and Thrombosis Research, Beth Israel Deaconess Medical Center and the Department of Medicine, Harvard Medical School, Boston, MA 02115, United States
    Crit Rev Oncol Hematol 62:126-36. 2007
    ....
  8. pmc The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size
    Jeffrey I Zwicker
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Blood 108:1280-3. 2006
    ....
  9. pmc Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)
    Jeffrey I Zwicker
    Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA Division of Hematology Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Br J Haematol 160:530-7. 2013
    ..Enoxaparin demonstrated a clear trend towards reducing the rate of VTE in patients with elevated levels of TFMP, with an overall rate of VTE similar in magnitude to the lower TFMP group...
  10. doi request reprint Tissue factor-bearing microparticles and thrombus formation
    Jeffrey I Zwicker
    Division of Hemostasis, Harvard Medical School, Thrombosis Beth Israel Deaconess Medical Center, 330 Brookline Ave E CLS 903, Boston, MA 02215, USA
    Arterioscler Thromb Vasc Biol 31:728-33. 2011
    ..Only a subpopulation of these microparticles expresses tissue factor...
  11. doi request reprint Accounting for death as a competing risk in cancer-associated thrombosis studies
    Federico Campigotto
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215 5450, USA
    Thromb Res 129:S85-7. 2012
    ..This review describes the theoretical and mathematical basis for estimating the cumulative incidence function by the competing risk model for the analysis of VTE outcomes in cancer-associated thrombosis...
  12. doi request reprint Timing of postpartum enoxaparin administration and severe postpartum hemorrhage
    Rachel A Freedman
    Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Blood Coagul Fibrinolysis 19:55-9. 2008
    ..Severe postpartum hemorrhage is an infrequent complication when enoxaparin is administered to hemostatically intact women between 5 and 24 h following a vaginal delivery or 12-36 h following cesarean section...

Research Grants2